Value investors are constantly searching for companies where the market price doesn’t fully reflect the underlying financial reality. One systematic way to identify such candidates is by running a 'Decent Value' screen. This approach filters for stocks that combine a strong fundamental valuation score—typically a ChartMill Valuation rating above 7 out of 10—with acceptable scores in profitability, financial health, and growth. The logic is straightforward: you want a company that is priced cheaply relative to its earnings and cash flows, but not because it is a broken business. Instead, the low valuation should be a potential anomaly, supported by solid operational metrics and a healthy balance sheet. This method helps investors avoid the classic value trap and focuses on firms where the fundamentals and the price may eventually align.
Pediatrix Medical Group Inc (NYSE:MD) is a company that stands out after applying such a screen. The firm is a leading provider of physician services for women, babies, and children, operating across the continuum of care—from hospital-based neonatal intensive care units (NICUs) to office-based pediatric subspecialties. With approximately 4,400 affiliated physicians and clinicians, Pediatrix plays a critical role in specialized and critical care. The company’s overall fundamental rating is a 6 out of 10, but it’s the specific components that make it interesting for value-oriented investors.
Valuation: A Core Strength
The most attractive argument for Pediatrix as a value stock lies in its valuation metrics. The ChartMill Valuation rating sits at an impressive 8 out of 10, which is a key requirement of the Decent Value screen. Looking at the numbers, the current Price/Earnings (P/E) ratio is 11.31, which is not only reasonable on an absolute basis but significantly cheaper than 91% of its peers in the Health Care Providers & Services industry. For context, the average P/E in the industry is around 54.50, and the S&P 500 average is approximately 26.91. Furthermore, the Price/Forward Earnings ratio stands at 9.98, again placing Pediatrix among the cheapest decile of its industry. The company also scores well on other price multiples: 84% of industry peers are more expensive based on the Enterprise Value to EBITDA ratio, and 90% are more expensive based on the Price/Free Cash Flow ratio.
For a value investor, a low valuation is the starting point. It provides a margin of safety, meaning that even if the company’s growth slows or expectations are slightly missed, the downside is somewhat cushioned by the already discounted price. Pediatrix’s valuation metrics clearly suggest it is trading at a significant discount to its peer group and the broader market, a core tenet of value investing.
Profitability: Solid Underlying Performance
While a low valuation is attractive, it must be backed by a profitable business. This is where Pediatrix delivers. The ChartMill Profitability rating is 7 out of 10, indicating above-average operational efficiency. The company’s Return on Assets (ROA) of 7.36% outperforms 88% of its industry peers. Similarly, the Return on Equity (ROE) is 19.10%, better than 86% of competitors, and the Return on Invested Capital (ROIC) of 9.88% ranks above 82% of its industry.
Importantly, the profit margins are also strong. The Profit Margin is 8.64%, which is superior to 92% of peer companies, and the Operating Margin of 12.07% beats 85% of the industry. Both margins have shown positive growth in recent years, which is a healthy sign. For value investors, high profitability and margins are crucial because they indicate that the company has a competitive advantage and can generate cash efficiently. A cheap stock with poor margins might be a value trap, but Pediatrix’s profitability metrics suggest the low valuation is not due to operational weakness.
Financial Health: Manageable Debt and Good Liquidity
A value candidate must also be financially stable. Pediatrix’s Health rating is 6 out of 10, which is decent but not flawless. The most positive aspect is the solvency picture. The Debt to Free Cash Flow (FCF) ratio is a healthy 2.36, meaning it would take just over two years of free cash flow to pay off total debt—this is better than 74% of industry peers. The company has also reduced its share count compared to both one and five years ago, which signals management confidence and a focus on shareholder value.
The company does carry some debt, with a Debt/Equity ratio of 0.66, but this is in line with the industry average. Liquidity is comfortable, with a Current Ratio of 1.66 and a Quick Ratio of 1.66, both of which are strong and rank in the top 30% of the industry. The Altman-Z score sits at 2.13, placing the company in the “grey zone” of bankruptcy risk, which is a neutral signal. Overall, the financial health is sufficient to support the business without posing immediate risks—a necessary condition for any value investment thesis.
Growth: A Decent but Mixed Picture
Growth is the component where Pediatrix scores lower, with a 4 out of 10 rating, which is typical for a value stock. The growth story is a bit of a mixed bag. On the positive side, Earnings Per Share (EPS) has grown by a 36.24% in the last year, and the average annual EPS growth over the past years is a solid 10.01%. This is an encouraging sign that the company is becoming more profitable on a per-share basis.
However, revenue tells a different story. The company experienced a -4.92% decline in revenue over the last year, which is a clear negative. The long-term average revenue growth is only 1.99% annually. Looking ahead, analysts expect EPS to grow by a modest 0.99% on average, while revenue is expected to grow by 3.93% annually. The deceleration in EPS growth from the past to the future is a cautionary point. Nevertheless, for a value investor, the combination of strong recent EPS growth, a cheap valuation, and solid profitability can offset slower top-line growth. The low PEG Ratio (NY) indicates that the current P/E is compensated by growth, further supporting the value case.
Analyst Views and Conclusion
Pediatrix Medical Group presents a textbook case for a Decent Value investment. It combines a cheap valuation (Valuation score of 8/10) with strong profitability (Profitability score of 7/10) and acceptable financial health (Health score of 6/10). While growth is moderate, the recent EPS surge and low valuation provide a favorable risk/reward proposition. The company’s critical role in neonatal and maternal-fetal medicine provides a defensive, recession-resistant element to its business model.
A full breakdown of the company’s financials can be found in the detailed fundamental analysis report on ChartMill here. For investors looking to identify similar opportunities with a strong valuation and decent fundamentals, the 'Decent Value' screen is a valuable tool. You can run this screen yourself and discover additional candidates by following this link: View more results from the Decent Value screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research or consult with a qualified financial professional before making any investment decisions.